Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II AUY922 monotherapy in previously treated advanced non-small-cell lung cancer
NL-OMON37940Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Luminespib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Clinical benefit at 18 weeks by RECIST. Started Nov 2011; status: active, not recruiting.
02
Drugs
Luminespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON37940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37940.